Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways without systematic review methods or new empirical data
PubMed 12419479 · doi:10.1016/s0002-9149(02)02749-2
What was done
The authors conducted a narrative review of the biochemical, metabolic, and genetic mechanisms underlying LDL heterogeneity, focusing on the enzymatic pathways generating small, dense LDL and its clinical role in coronary artery disease and the metabolic syndrome.
What was found
The abstract reports no new primary quantitative clinical trial or observational data, other than noting that traditional risk factors predict about 50% of CAD risk. It synthesizes the metabolic pathway: hepatic overproduction of large VLDL, increased free fatty acid flux from insulin-resistant adipocytes, lipid exchange mediated by CETP, and subsequent triglyceride hydrolysis by hepatic lipase to form small, dense LDL. Small, dense LDL particles exhibit prolonged plasma residence time, decreased LDL receptor binding, increased oxidation susceptibility, enhanced arterial wall entry and retention, and promotion of endothelial dysfunction.
Why it matters
This review explains why individuals with normal or borderline LDL cholesterol levels can still harbor substantial atherogenic risk driven by elevated numbers of small, dense LDL particles, low HDL, and hypertriglyceridemia.
Limits
The paper is a narrative review with no systematic search protocol, meta-analysis, or primary human dataset. No sample size, relative risk metrics, or confidence intervals are provided in the abstract.
Cited by
- supports Lipase breaks down triglycerides in VLDL particles, causing them to shrink and lose triglyceride while retaining most cholesterol, converting them into small, dense LDL particles.